Lord, Abbett & Co
IPXL

Lord, Abbett & Co’s Impax Laboratories, Inc. IPXL Stock Holding History

Lord, Abbett & Co’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,273,131
Closed -$38.2M – 1068
2014
Q2 		$38.2M Buy
+1,273,131
New +$34.3M 0.09% 338

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Lord, Abbett & Co's IPXL Position: Q3 2014 in Review

Lord, Abbett & Co sold out of Impax Laboratories, Inc. (IPXL) in Q3 2014, closing a stake of 1,273,131 shares — an estimated $38.2M sold.

Lord, Abbett & Co first reported a position in IPXL in Q2 2014 and held it in 1 quarter. The position peaked at $38.2M in Q2 2014. 162 funds tracked by Wall St. Rank hold IPXL as of Q3 2014.

  • Lord, Abbett & Co reported no remaining Impax Laboratories, Inc. position as of Q3 2014 after selling out during the quarter.
  • Lord, Abbett & Co sold 1,273,131 Impax Laboratories, Inc. shares in Q3 2014, an estimated $38.2M.
  • Lord, Abbett & Co first reported a position in Impax Laboratories, Inc. in Q2 2014 and held it in 1 quarter.
  • Lord, Abbett & Co's Impax Laboratories, Inc. position peaked at $38.2M in Q2 2014.
  • 162 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2014.

Based on Lord, Abbett & Co's 13F filing for Q3 2014, filed 14 Nov 2014.